hydroxyproline has been researched along with Cancer of Prostate in 52 studies
Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.
hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Urinary hydroxyproline was elevated significantly in patients with untreated stage D prostatic carcinoma when compared to values in patients with benign prostatic hypertrophy and prostatic carcinoma without bony metastasis." | 7.66 | Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate. ( Kim, H; Mooppan, MM; Tobin, MS; Wang, JC; Wax, SH, 1980) |
| "Patients with skeletal metastases (n = 24) showed significantly higher hydroxyproline excretion in the urine than did those with prostate cancer without metastases, or healthy men of the same age (n = 35)." | 5.26 | Urinary hydroxyproline in healthy patients and in prostate patients with and without bone metastases. ( Bichler, KH; Harzmann, R; Heller, W; Schmidt, K, 1979) |
| "21 patients had bone metastases diagnosed by bone scanning (99mTc MDP)." | 5.26 | Urine hydroxyproline excretion--a marker of bone metastases in prostatic carcinoma. ( Bishop, MC; Fellows, GJ, 1977) |
| "Urinary hydroxyproline was elevated significantly in patients with untreated stage D prostatic carcinoma when compared to values in patients with benign prostatic hypertrophy and prostatic carcinoma without bony metastasis." | 3.66 | Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate. ( Kim, H; Mooppan, MM; Tobin, MS; Wang, JC; Wax, SH, 1980) |
| "A rapid and significant suppression of bone resorption was observed in all patients after intravenous treatment." | 2.69 | Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. ( Hamdy, NA; Lycklama à Nijeholt, AA; Papapoulos, SE; Pelger, RC; Zwinderman, AH, 1998) |
| "The most reliable laboratory test for prostate cancer remains prostatic phosphatase determination." | 2.36 | [Laboratory tools in the diagnosis of prostatic cancer (author's transl)]. ( Jacobi, GH, 1979) |
| "Two of the patients had primary prostate cancer and one had a squamous cell lung tumour." | 1.43 | Inhibition of cancer cell mitosis by reducing the availability of phosphate. ( Condon, JR, 2016) |
| "Alendronate failed to inhibit MMP-2 activity directly, but instead appeared to block cellular secretion of MMP-2." | 1.30 | Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. ( Stearns, ME, 1998) |
| "The present open study included 16 prostate cancer patients who had painful bone metastases and who had failed hormonal therapy." | 1.29 | The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. ( Kylmälä, T; Lindholm, TS; Seppänen, J; Tammela, TL, 1994) |
| "Patients with Hodgkin's disease had elevated T, D, and ND HYPRO levels, and the D/ND ratio was in the range of patients with prostate cancer." | 1.27 | Total, dialyzable, and nondialyzable postabsorptive hydroxyproline. Values in patients with cancer. ( Hopkins, SC; Maxwell, TA; Neely, CL; Niell, HB; Palmieri, GM; Soloway, MS, 1983) |
| "In patients with prostatic cancer--the ones with bone metastases proved by bone scanning--urinary HOP levels were found to be 69." | 1.27 | Urinary hydroxyproline levels in patients with prostatic carcinoma. ( Adalar, N; Erol, D; Güvençli, S; Simşek, F, 1983) |
| "In metastatic prostate cancer where blastic osseous metastases predominate, disease progression on bone scan correlated with elevation of both total hydroxyproline excretion (7." | 1.27 | Total and nondialyzable hydroxyproline excretion in Stage D2 prostate cancer. ( Hopkins, SC; Moinuddin, M; Niell, HB; Palmieri, GM; Soloway, MS, 1984) |
| "Thirty-two men with stage D2 prostatic cancer were monitored by bone scan, acid and alkaline phosphatase values, and urinary hydroxyproline, beginning from 4 to 36 months after initiation of hormonal manipulation and/or systemic chemotherapy." | 1.27 | Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer. ( Hopkins, SC; Ikard, M; Moinuddin, M; Nissenkorn, I; Palmieri, GM; Soloway, MS, 1983) |
| "Both were elevated in patients with prostatic cancer with active bone metastases compared to the values of prostatic cancer without bone metastasis and benign prostatic hypertrophy." | 1.27 | [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)]. ( Imai, K; Kitaura, K; Kurokawa, K; Tomaru, Y; Yamanaka, H, 1985) |
| "Increases without any evidence of metastases are either due to other diseases with connective tissue changes or to occult micrometastases." | 1.27 | [The value of the free hydroxyproline and the N-acetyl-beta- glucosaminidase for the observation of the course of malignant tumors]. ( Lange, H; Müller, A; Ruffert, K, 1986) |
| " It is concluded that PIP activity dosage in serum may provide with urinary hydroxyproline, further information for the study of collagen metabolism in osteoblastic bone diseases during treatment." | 1.27 | [Determination of serum proline iminopeptidase activity using a fluorescent substrate in patients with Paget's disease and prostatic bone metastases. Preliminary results]. ( Bouvier, M; Colson, F; Mathieu, M; Tebib, J; Vianey-Liaud, C, 1986) |
| "In 25 patients with prostatic cancer and 26 patients with benign prostatic hypertrophy, urinary hydroxyproline excretion as estimated by the method described by Cleary and Saunders." | 1.26 | Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer. ( Aoyagi, K; Rinsho, K, 1982) |
| "Of 31 patients with prostatic cancer, 21 have skeletal metastases proven by bone scintigraphy and/or radiology." | 1.26 | [Urinary and serum hydroxyproline in the diagnosis of bone metastases of prostatic cancer]. ( Courvoisier, B; Depierre, D; Gasser, AB; Jeannet, C, 1981) |
| "Patients with skeletal metastases (n = 24) showed significantly higher hydroxyproline excretion in the urine than did those with prostate cancer without metastases, or healthy men of the same age (n = 35)." | 1.26 | Urinary hydroxyproline in healthy patients and in prostate patients with and without bone metastases. ( Bichler, KH; Harzmann, R; Heller, W; Schmidt, K, 1979) |
| "21 patients had bone metastases diagnosed by bone scanning (99mTc MDP)." | 1.26 | Urine hydroxyproline excretion--a marker of bone metastases in prostatic carcinoma. ( Bishop, MC; Fellows, GJ, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 43 (82.69) | 18.7374 |
| 1990's | 8 (15.38) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (1.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Condon, JR | 1 |
| RUBEGNI, M | 1 |
| RAVENNI, G | 1 |
| DEL GIOVANE, L | 1 |
| Platt, WD | 1 |
| Doolittle, LH | 1 |
| Hartshorn, JW | 1 |
| Catalona, WJ | 1 |
| Menon, M | 1 |
| Rinsho, K | 3 |
| Unni Mooppan, MM | 1 |
| Kim, H | 2 |
| Wang, JC | 2 |
| Tobin, MS | 2 |
| Wax, SH | 2 |
| Schacht, MJ | 1 |
| Garnett, JE | 1 |
| Grayhack, JT | 1 |
| Romics, I | 2 |
| Lengyel, L | 1 |
| Nemoto, S | 1 |
| Niell, HB | 2 |
| Palmieri, GM | 3 |
| Neely, CL | 1 |
| Maxwell, TA | 1 |
| Hopkins, SC | 3 |
| Soloway, MS | 3 |
| Erol, D | 1 |
| Adalar, N | 1 |
| Güvençli, S | 1 |
| Simşek, F | 1 |
| Moinuddin, M | 2 |
| Kelleher, PC | 1 |
| Smith, CJ | 1 |
| Nissenkorn, I | 1 |
| Ikard, M | 1 |
| Aoyagi, K | 1 |
| Gasser, AB | 1 |
| Jeannet, C | 1 |
| Depierre, D | 1 |
| Courvoisier, B | 1 |
| Posma, FD | 1 |
| Groenewold, H | 1 |
| Kluft, O | 1 |
| Tuynman, FH | 1 |
| Feustel, A | 1 |
| Budavári, I | 1 |
| Kisbenedek, L | 1 |
| Balogh, F | 1 |
| Mooppan, MM | 1 |
| Miyamoto, KK | 1 |
| McSherry, SA | 1 |
| Robins, SP | 1 |
| Besterman, JM | 1 |
| Mohler, JL | 1 |
| Alcover, J | 1 |
| Fernández-Conde, M | 1 |
| Filella, X | 1 |
| de Osaba, MJ | 1 |
| Carretero, P | 1 |
| Kylmälä, T | 1 |
| Tammela, TL | 1 |
| Lindholm, TS | 1 |
| Seppänen, J | 1 |
| Dreicer, R | 1 |
| Kemp, JD | 1 |
| Stegink, LD | 1 |
| Cardillo, T | 1 |
| Davis, CS | 1 |
| Forest, PK | 1 |
| See, WA | 1 |
| Pelger, RC | 1 |
| Hamdy, NA | 1 |
| Zwinderman, AH | 1 |
| Lycklama à Nijeholt, AA | 1 |
| Papapoulos, SE | 1 |
| Stearns, ME | 1 |
| Harzmann, R | 2 |
| Bichler, KH | 2 |
| Jacobi, GH | 1 |
| Heller, W | 1 |
| Schmidt, K | 1 |
| Pust, R | 1 |
| Rost, A | 1 |
| Weidner, W | 1 |
| Rothauge, CF | 1 |
| Mundy, AR | 1 |
| Bishop, MC | 1 |
| Fellows, GJ | 1 |
| Roques, CF | 1 |
| Mazières, B | 1 |
| Amigues, H | 1 |
| Fournie, A | 1 |
| Arlet, J | 1 |
| Ruffié, R | 1 |
| Clarke, NW | 2 |
| McClure, J | 2 |
| George, NJ | 2 |
| Holbrook, IB | 1 |
| Kurokawa, K | 1 |
| Imai, K | 1 |
| Yamanaka, H | 1 |
| Tomaru, Y | 1 |
| Kitaura, K | 1 |
| Ruffert, K | 1 |
| Müller, A | 1 |
| Lange, H | 1 |
| Urwin, GH | 1 |
| Percival, RC | 1 |
| Yates, AJ | 1 |
| Watson, ME | 1 |
| Couch, M | 1 |
| McDonald, B | 1 |
| Forrest, AR | 1 |
| Williams, JL | 1 |
| Kanis, JA | 1 |
| O'Brien, WM | 1 |
| Lynch, JH | 1 |
| Kawamura, J | 1 |
| Tochigi, H | 1 |
| Yanagawa, M | 1 |
| Yoshida, O | 1 |
| Hida, S | 1 |
| Mori, O | 1 |
| Suzuki, N | 1 |
| Saito, K | 1 |
| Komatsu, Y | 1 |
| Hatayama, T | 1 |
| Francini, G | 1 |
| Bigazzi, S | 1 |
| Leone, V | 1 |
| Gennari, C | 1 |
| Scher, HI | 1 |
| Curley, T | 1 |
| Geller, N | 1 |
| Dershaw, D | 1 |
| Chan, E | 1 |
| Nisselbaum, J | 1 |
| Alcock, N | 1 |
| Hollander, P | 1 |
| Yagoda, A | 1 |
| Bouvier, M | 1 |
| Colson, F | 1 |
| Tebib, J | 1 |
| Mathieu, M | 1 |
| Vianey-Liaud, C | 1 |
| Charhon, SA | 1 |
| Chapuy, MC | 1 |
| Delvin, EE | 1 |
| Meunier, PJ | 1 |
| Kontturi, MJ | 1 |
| Sotaniemi, EA | 1 |
| Larmi, TK | 1 |
| Matsushita, Y | 1 |
| Hasegawa, K | 1 |
| Sugimura, R | 1 |
| Otomo, S | 1 |
| Morii, H | 1 |
| Cerda, JJ | 1 |
| Toskes, PP | 1 |
| Shopa, NA | 1 |
| Wilkinson, JH | 1 |
| Katz, FH | 1 |
| Kappas, A | 1 |
| Kerkhoff, JF | 1 |
| Guzzo, CE | 1 |
| Pachas, WN | 1 |
| Pinals, RS | 1 |
| Krant, MJ | 1 |
| Hosley, HF | 1 |
| Taft, EG | 1 |
| Olson, KB | 1 |
| Gates, S | 1 |
| Beebe, RT | 1 |
| Immergut, M | 1 |
| Nordschow, CD | 1 |
| Tammes, AR | 1 |
| Flocks, RH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for hydroxyproline and Cancer of Prostate
| Article | Year |
|---|---|
Biochemical markers in prostatic cancer.
Topics: Acid Phosphatase; Alkaline Phosphatase; alpha-Fetoproteins; Amino Acids; Antigens, Neoplasm; Body Fl | 1984 |
Collagen metabolites in the urine and serum of patients with cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Collagen; Colorimetry; Female; Humans; Hydroxylysine; Hydroxyproli | 1982 |
[Laboratory tools in the diagnosis of prostatic cancer (author's transl)].
Topics: Acid Phosphatase; Alkaline Phosphatase; Androstanes; Bone Marrow; Carcinoembryonic Antigen; False Ne | 1979 |
5 trials available for hydroxyproline and Cancer of Prostate
| Article | Year |
|---|---|
A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Creatinine; Deferoxami | 1997 |
Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Bone Neo | 1998 |
Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer.
Topics: Alkaline Phosphatase; Bone Neoplasms; Bone Resorption; Calcium; Creatinine; Diphosphonates; Humans; | 1992 |
Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone and Bones; Diphosphonates; Humans; Hydroxyproline; | 1991 |
Gallium nitrate in prostatic cancer: evaluation of antitumor activity and effects on bone turnover.
Topics: Adenocarcinoma; Aged; Bone and Bones; Bone Neoplasms; Bone Resorption; Calcium; Clinical Trials as T | 1987 |
44 other studies available for hydroxyproline and Cancer of Prostate
| Article | Year |
|---|---|
Inhibition of cancer cell mitosis by reducing the availability of phosphate.
Topics: Acid Phosphatase; Alkaline Phosphatase; Bone and Bones; Carcinoma, Squamous Cell; Glucagon; Humans; | 2016 |
[Increase of urinary elimination of hydroxyproline in osteolytic processes].
Topics: Bone Neoplasms; Breast Neoplasms; Humans; Hydroxyproline; Male; Neoplasm Metastasis; Prostatic Neopl | 1962 |
URINARY HYDROXYPROLINE EXCRETION IN METASTATIC CANCER OF BONE.
Topics: Acid Phosphatase; Biomedical Research; Bone Neoplasms; Breast Neoplasms; Collagen; Humans; Hydroxypr | 1964 |
New screening and diagnostic tests for prostate cancer and immunologic assessment.
Topics: alpha-Fetoproteins; Antigens, Neoplasm; Carcinoembryonic Antigen; Cholesterol; Chorionic Gonadotropi | 1981 |
[Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer].
Topics: Aged; Bone Neoplasms; Humans; Hydroxyproline; Male; Middle Aged; Prostatic Hyperplasia; Prostatic Ne | 1983 |
Use of urinary hydroxyproline excretion as a tumor marker in diagnosis and follow-up of prostatic carcinoma.
Topics: Bone Neoplasms; Castration; Creatinine; Estrogens; Follow-Up Studies; Humans; Hydroxyproline; Male; | 1983 |
Study of serum and urine hydroxyproline level of patients with prostatic cancer.
Topics: Aged; Bone Neoplasms; Humans; Hydroxyproline; Male; Middle Aged; Prostatic Neoplasms | 1984 |
[Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer (II): Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and tumor markers in blood and urine].
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Creatine; Humans; Hydroxyproline; Male; | 1984 |
Total, dialyzable, and nondialyzable postabsorptive hydroxyproline. Values in patients with cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Collagen; Dialysis; Female; Hodgkin Disease; Humans; Hydroxyprolin | 1983 |
Urinary hydroxyproline levels in patients with prostatic carcinoma.
Topics: Aged; Bone Neoplasms; Humans; Hydroxyproline; Male; Middle Aged; Prostatic Neoplasms | 1983 |
Total and nondialyzable hydroxyproline excretion in Stage D2 prostate cancer.
Topics: Adenocarcinoma; Bone Neoplasms; Collagen; Creatinine; Dialysis; Humans; Hydroxyproline; Male; Neopla | 1984 |
Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer.
Topics: Acid Phosphatase; Adenocarcinoma; Alkaline Phosphatase; Bone Neoplasms; Creatinine; Humans; Hydroxyp | 1983 |
Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer.
Topics: Bone Neoplasms; Creatinine; Humans; Hydroxyproline; Male; Prostatic Neoplasms | 1982 |
[Urinary and serum hydroxyproline in the diagnosis of bone metastases of prostatic cancer].
Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; Bone Neoplasms; Calcium; Creatinine; Humans; Hydroxypr | 1981 |
Reference values and analytical performance of the hydroxyproline/creatinine ratio in early morning urine samples.
Topics: Adult; Aged; Breast Neoplasms; Creatinine; Fasting; Female; Humans; Hydroxyproline; Male; Middle Age | 1981 |
[Modern developments in the diagnosis and therapy of prostatic cancer].
Topics: Acid Phosphatase; Age Factors; Bone Neoplasms; Cyclophosphamide; Estrogens; Humans; Hydroxyproline; | 1981 |
Study of hydroxyproline excretion in patients with prostatic cancer.
Topics: Bone Neoplasms; Humans; Hydroxyproline; Male; Prostatic Neoplasms | 1981 |
Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate.
Topics: Bone Neoplasms; Carcinoma; Humans; Hydroxyproline; Male; Neoplasm Staging; Prostatic Neoplasms | 1980 |
Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
Topics: Aged; Amino Acids; Biomarkers, Tumor; Bone Neoplasms; Circadian Rhythm; Collagen; Creatinine; Humans | 1994 |
[Correlation between bone gammagraphy and biochemical parameters in bone turnover in patients with prostate cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Creatinine; Humans; Hydroxyproline; | 1994 |
The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Clodronic Acid; Dose | 1994 |
Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells.
Topics: Alendronate; Antineoplastic Agents; Bone Neoplasms; Collagen; Gelatinases; Humans; Hydroxyproline; M | 1998 |
[Current status of diagnosis and stage classification of prostatic carcinoma].
Topics: Aged; Biopsy, Needle; Bone Neoplasms; Humans; Hydroxyproline; Lymphatic Metastasis; Male; Middle Age | 1977 |
Urinary hydroxyproline in healthy patients and in prostate patients with and without bone metastases.
Topics: Bone Neoplasms; Humans; Hydroxyproline; Male; Neoplasm Metastasis; Prostatic Neoplasms; Radiography | 1979 |
[Evaluation of hydroxyproline excretion in the urine (UHP) in prostate carcinoma].
Topics: Aged; Bone Neoplasms; Carcinoma; Castration; False Negative Reactions; False Positive Reactions; Hum | 1979 |
Urinary hydroxyproline excretion in carcinoma of the prostate. A comparison of 4 different modes of assessment and its role as a marker.
Topics: Aged; Bone Neoplasms; Creatinine; Follow-Up Studies; Humans; Hydroxyproline; Male; Middle Aged; Pros | 1979 |
Urine hydroxyproline excretion--a marker of bone metastases in prostatic carcinoma.
Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; Bone Neoplasms; Calcium; Creatinine; Humans; Hydroxypr | 1977 |
[Chromatographic analysis of urinary amino acids in Paget's disease. II : clinical study].
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Amino Acids; Bone Diseases; Bone Neoplasms; Calcitoni | 1976 |
[Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
Topics: Bone Neoplasms; Humans; Hydroxyproline; Male; Prostatic Hyperplasia; Prostatic Neoplasms | 1985 |
[The value of the free hydroxyproline and the N-acetyl-beta- glucosaminidase for the observation of the course of malignant tumors].
Topics: Acetylglucosaminidase; Bone Neoplasms; Breast Neoplasms; Female; Hexosaminidases; Hodgkin Disease; H | 1986 |
Biochemical markers and skeletal metabolism in carcinoma of the prostate. Use of decision matrix theory and ROC analysis.
Topics: 6-Ketoprostaglandin F1 alpha; Bone and Bones; Bone Neoplasms; Calcium; Calcium-Binding Proteins; Hum | 1985 |
Hydroxyproline as a marker for following patients with metastatic prostate cancer.
Topics: Bone Neoplasms; Buserelin; Creatinine; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; | 1988 |
[Effects of etidronate disodium (EHDP) on urogenital malignancies with bone metastasis: a multicentered collaborative evaluation].
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Calcium; Drug Evaluat | 1988 |
Serum osteocalcin concentration in patients with prostatic cancer.
Topics: 1-Carboxyglutamic Acid; Acid Phosphatase; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers, | 1988 |
[Determination of serum proline iminopeptidase activity using a fluorescent substrate in patients with Paget's disease and prostatic bone metastases. Preliminary results].
Topics: Adult; Aminopeptidases; Bone Neoplasms; Coumarins; Female; Humans; Hydroxyproline; Male; Middle Aged | 1986 |
Parathyroid function and vitamin D status in patients with bone metastases of prostatic origin.
Topics: Aged; Alkaline Phosphatase; Bone Neoplasms; Calcifediol; Calcitriol; Calcium; Humans; Hydroxyproline | 1985 |
Hydroxyproline in the early diagnosis of bone metastases in prostatic cancer.
Topics: Administration, Oral; Aged; Bone Neoplasms; Diethylstilbestrol; Humans; Hydroxyproline; Injections, | 1974 |
Effect of calcitonin and hexestrol on urinary excretion of hydroxyproline in a patient with prostatic cancer and bone metastases.
Topics: Acid Phosphatase; Alkaline Phosphatase; Bone Neoplasms; Calcitonin; Calcium; Hexestrol; Humans; Hydr | 1974 |
The relationship of the serum alkaline phosphatase to urinary hydroxyproline excretion in liver and bone diseases.
Topics: Acromegaly; Adult; Aged; Alkaline Phosphatase; Blood Protein Electrophoresis; Bone Diseases; Cholest | 1970 |
Influence of estradiol and estriol on urinary excretion of hydroxyproline in man.
Topics: Acromegaly; Adult; Aged; Breast Neoplasms; Creatinine; Estradiol; Estriol; Estrogens; Female; Growth | 1968 |
A rapid serum screening test for increased osteoblastic activity.
Topics: Adolescent; Adult; Alkaline Phosphatase; Blood Chemical Analysis; Bone and Bones; Bone Development; | 1968 |
Urinary hydroxyproline excretion in patients with cancer.
Topics: Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Calcium; Collagen; Creatine; Female; Humans; | 1969 |
Hydroxyproline excretion in malignant neoplastic disease.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Carcinoma, Bronchogenic; Female | 1966 |
Urinary hydroxyproline excretion in patients with metastatic carcinoma of the prostate.
Topics: Humans; Hydroxyproline; Male; Neoplasm Metastasis; Prostatic Neoplasms | 1966 |